[Eradication effect of lansoprazole-based triple therapy against H. pylori]

Eradication of H. pylori provides a potential cure in the majority of patients with gastric ulcer as well as duodenal ulcer. Two proton pump inhibitor(PPI)-based triple therapy, combining with clarithromycin(CAM), amoxicillin(AMPC) or metronidazole have been established as standard regimens worldwide. In Japan, lansoprazole(LPZ)-based triple therapy combined with CAM and AMPC for 1 week was firstly investigated on eradication effect against H. pylori and determination of the optimal dose of CAM in multicenter, double-blind trial. Patients with active gastric ulcer or duodenal ulcer were enrolled in this study. The eradication rate of H. pylori in patients with gastric ulcer were 0%, 87.5% and 89.2% and those in patients with duodenal ulcer were 4.4%, 91.1% and 83.7% in LPZ(60 mg/d) alone, LPZ(60 mg/d) with CAM(400 mg/d) and AMPC(1,500 mg/d), LPZ(60 mg/d) with CAM(800 mg/d) and AMPC(1,500 mg/d), respectively, in the full set analysis. LPZ-based triple therapy demonstrated a high eradication rate and was safe. In addition, the combination regimens with lower or higher dose of CAM were equivalent in Japanese patients.